{
  "docId": "019dd923-622c-750b-8b98-17b017c6aac8",
  "docSlug": "384ff8288d23",
  "documentTitle": "Acutus Medical Inc. (AFIB)",
  "authorId": "53_Kerrisdale_Capital",
  "authorName": "Kerrisdale Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 6,
  "pageCount": 29,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "executive_summary",
  "function": "size_opportunity",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "Kerrisdale Capital research note page 6.",
  "elementsJson": [
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b98-17b017c6aac8/6",
  "deckHref": "/decks/019dd923-622c-750b-8b98-17b017c6aac8",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b98-17b017c6aac8.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b98-17b017c6aac8#slide-6",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "At its current $480 million market capitalization, investors have an extraordinary opportunity to ride that wave of growth at an incredibly attractive entry point.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-fb8f-761b-afcc-802a5370d733",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "TAM: $15 billion",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-fb8f-761b-afcc-87aaa564e1f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.235,
        "w": 0.766,
        "x": 0.117,
        "y": 0.108
      },
      "kind": "paragraph",
      "text": "The total addressable market (TAM) for Acutus’s product offering is massive, and AcQMap is the only product of its kind within that market. The global market for ablation disposables is approximately $5-6 billion. While that’s grown at a mid-teens percentage rate over the last five years, we expect new technologies – including Acutus’s non-contact mapping and the introduction of pulsed field ablation (PFA) – will make the performance of the procedure faster, safer, and more effective, leading to an acceleration in the growth of the market. In five years, we expect the overall market to exceed $15 billion globally.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1db08fa9-cb68-4414-b792-daab505d5667",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.455,
        "w": 0.766,
        "x": 0.117,
        "y": 0.261
      },
      "kind": "paragraph",
      "text": "Acutus’s current product lineup, which includes its mapping catheter in the US and Europe, as well as its radiofrequency ablation catheter only in Europe, addresses about 60-70% of the current market. In the next 18-24 months, we expect Acutus’s ablation catheter to be approved in the US, giving it entrée to the rest of the ablation TAM. Beyond that, Acutus is in the process of developing its own PFA catheter optimized to ablate non-PV triggers in persistent AF, and expects trials to begin next year. Given the game-changing nature of AcQMap technology, we expect that Acutus’s market share will easily exceed 10% over time, while reaching much higher levels in the niches of complex arrhythmias like persistent AF, redo procedures, and supraventricular tachycardias. A successful ablation catheter and PFA product will result in even more dramatic market share gains. Acutus may be in the very early stages of commercializing its technology, but its groundbreaking nature will allow it to sustain extraordinary levels of revenue growth for at least the next decade and possibly beyond. At its current $480 million market capitalization, investors have an extraordinary opportunity to ride that wave of growth at an incredibly attractive entry point.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b1d4030-eecf-4cbe-8c65-fe417856700f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "4a6e2fa9-d5a2-48b8-8bbf-7b1cf6724290",
      "evidence": "The total addressable market (TAM) for Acutus’s product offering is massive, and AcQMap is the only product of its kind within that market.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}